Loading...
CSL logo
CSL
CSL

Margin Recovery And Operating Model Simplification Will Support A Stronger Long Term Outlook

Published
06 Jan 26
Views
360
n/a
n/a
AnalystHighTarget's Fair Value
n/a
Loading
1Y
-33.3%
7D
1.9%

Author's Valuation

AU$289.3737.7% undervalued intrinsic discount

AnalystHighTarget Fair Value

Narrative
Updates0

Catalysts

About CSL

CSL is a global biopharmaceutical group focused on plasma derived therapies, vaccines and specialty medicines for rare and serious diseases.

What are the underlying business or industry changes driving this perspective?

  • The company is targeting more than US$0.5b in annual pretax savings by the end of FY28 from a simpler operating model, site consolidation and process efficiencies, which gives room to support earnings and operating margin while still funding growth initiatives.
  • Management plans to reinvest roughly half of these savings into higher priority clinical and commercial opportunities, such as Phase I and II programs and indication expansions, which can support longer term revenue and NPATA growth.
  • The intent to demerge CSL Seqirus into a separate ASX listed entity is expected to reduce complexity and allow both businesses to focus on their core capabilities, which can support more focused capital allocation and potentially higher group earnings quality.
  • CSL reports strong demand across core Ig indications such as PID, SID and CIDP, together with targeted channel expansion and diagnosis efforts. Management links this to a positive outlook for Ig volumes and a mix shift toward higher margin HIZENTRA that can support Behring gross margin and group profit.
  • Newer therapies and launches such as ANDEMBRY in HAE, HEMGENIX in hemophilia B, TAVNEOS and FILSPARI in nephrology, and Ferinject expansion in markets like China and intercontinental regions are expected to widen CSL's addressable patient base and support revenue and operating profit growth across multiple business units.
  • Completed rollout of the RIKA plasmapheresis system and iNomi platform, together with ongoing yield improvements and closure of underperforming plasma centers, are intended to reduce cost per liter and improve manufacturing efficiency. This is aimed at supporting Behring gross margin and overall net margins over time.
ASX:CSL Earnings & Revenue Growth as at Jan 2026
ASX:CSL Earnings & Revenue Growth as at Jan 2026

Assumptions

This narrative explores a more optimistic perspective on CSL compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

  • The bullish analysts are assuming CSL's revenue will grow by 5.8% annually over the next 3 years.
  • The bullish analysts assume that profit margins will increase from 19.3% today to 24.0% in 3 years time.
  • The bullish analysts expect earnings to reach $4.4 billion (and earnings per share of $9.07) by about January 2029, up from $3.0 billion today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $3.8 billion.
  • In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 26.0x on those 2029 earnings, up from 18.5x today. This future PE is greater than the current PE for the AU Biotechs industry at 18.5x.
  • The bullish analysts expect the number of shares outstanding to remain consistent over the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 7.0%, as per the Simply Wall St company report.
ASX:CSL Future EPS Growth as at Jan 2026
ASX:CSL Future EPS Growth as at Jan 2026

Risks

What could happen that would invalidate this narrative?

  • CSL Behring’s gross margin recovery depends on multiple levers working together, including yield gains, mix shift toward higher margin HIZENTRA, closures of underperforming plasma centers and lower donor fees. Management has explicitly stepped back from giving a time frame to return to historical margin levels, so any prolonged pressure from product mix, labor costs or foreign exchange could cap margin improvement and weigh on earnings and net margins.
  • The plan to achieve more than US$0.5b in annual pretax savings by FY28 requires large headcount reductions, R&D restructuring, European Works Council processes and plasma network optimization. If execution is slower or more expensive than expected, the one off FY26 restructuring costs of about US$560m to US$620m after tax could be followed by lower than planned ongoing savings, limiting the support to future profit growth and free cash flow.
  • Several key franchises face intensifying competition and pricing pressure over the long term, including Ig tenders where CSL is already walking away from low priced contracts, iron therapies like Ferinject in Europe where generics are entering, and the influenza vaccine business where peers are competing aggressively on price in egg based products. Sustained pressure in any of these areas could constrain revenue growth and compress segment margins.
  • Policy and regulatory risks are building in CSL’s core markets, with U.S. IRA Part D reform already affecting Ig revenue, ongoing discussion of pharmaceutical sector tariffs, and uncertainty around Most Favored Nation pricing. Any adverse policy outcome that cannot be offset through pricing or supply chain adjustments could reduce revenue, disturb regional profit mix and lift the effective tax rate, which would affect NPAT and returns on invested capital.
  • The intent to demerge CSL Seqirus by the end of FY26 and to rework the operating model across R&D, commercial and medical functions introduces structural and execution risk. If the separation or integration of functions distracts management, increases duplicated costs such as overlapping manufacturing footprints, or weakens product launch momentum in areas like ANDEMBRY or HEMGENIX, that could slow revenue growth and delay expected improvements in operating margins and earnings.
Curious how numbers become stories that shape markets? Explore Community Narratives

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The assumed bullish price target for CSL is A$289.37, which represents up to two standard deviations above the consensus price target of A$233.85. This valuation is based on what can be assumed as the expectations of CSL's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of A$289.37, and the most bearish reporting a price target of just A$186.78.
  • In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $18.4 billion, earnings will come to $4.4 billion, and it would be trading on a PE ratio of 26.0x, assuming you use a discount rate of 7.0%.
  • Given the current share price of A$172.46, the analyst price target of A$289.37 is 40.4% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on CSL?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

CSL logo
CSL

Seqirus Demerger And Cost Savings Will Shape A Steady Long Term Outlook

Catalysts About CSL CSL is a global biopharmaceutical group focused on plasma therapies, vaccines and specialty medicines addressing rare and serious diseases. What are the underlying business or industry changes driving this perspective?
View narrative
AU$180.87
FV
0.3% undervalued intrinsic discount
2.87%
Revenue growth p.a.
2
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
CSL logo
CSL

CSL will thrive with an 18% profit surge ahead

this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam this is spam
View narrative
AU$239.81
FV
24.8% undervalued intrinsic discount
6.48%
Revenue growth p.a.
54
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative